U.S. Markets close in 5 hrs 32 mins
  • S&P 500

    3,684.30
    +17.58 (+0.48%)
     
  • Dow 30

    30,093.21
    +123.69 (+0.41%)
     
  • Nasdaq

    12,412.30
    +35.12 (+0.28%)
     
  • Russell 2000

    1,863.08
    +14.38 (+0.78%)
     
  • Crude Oil

    46.02
    +0.38 (+0.83%)
     
  • Gold

    1,840.70
    -0.40 (-0.02%)
     
  • Silver

    24.23
    +0.09 (+0.36%)
     
  • EUR/USD

    1.2151
    +0.0001 (+0.0121%)
     
  • 10-Yr Bond

    0.9730
    +0.0530 (+5.76%)
     
  • Vix

    20.83
    -0.45 (-2.11%)
     
  • GBP/USD

    1.3490
    +0.0037 (+0.2752%)
     
  • USD/JPY

    104.1200
    +0.2600 (+0.2503%)
     
  • BTC-USD

    18,999.77
    -257.81 (-1.34%)
     
  • CMC Crypto 200

    372.69
    -6.56 (-1.73%)
     
  • FTSE 100

    6,549.15
    +58.88 (+0.91%)
     
  • Nikkei 225

    26,751.24
    -58.13 (-0.22%)
     

Geron to Present at the Stifel Virtual Healthcare Conference

·1 min read

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Chairman and Chief Executive Officer, will present a company overview at the Stifel Virtual Healthcare Conference on Tuesday, November 17, 2020 at 2:40 p.m. ET.

A live audio webcast of the presentation will be available on Geron’s website, www.geron.com/investors/events. If you are unable to listen to the live presentation, an archived webcast will be available on the Company’s website for 30 days.

About Geron

Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. For more information about Geron, visit www.geron.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201110006086/en/

Contacts

Suzanne Messere
Investor and Media Relations
investor@geron.com
media@geron.com